Pfizer and Astellas said the regimen became the first platinum-free option for adult muscle-invasive bladder cancer regardless of cisplatin eligibility, backed by EV-304 data showing lower recurrence risk and improved survival.
verifying reliability
No specialized terms available for this topic.